FDA committee agrees Biogen’s ALS therapy could have ‘clinical benefit’
A US FDA panel of advisors concluded that there was a lack of substantial evidence to indicate that Biogen’s investigational drug, tofersen, was effective in treating a rare and aggressive form of ALS. But the experts voted unanimously that the investigational product could have a clinical benefit in reducing a protein that is associated with disease severity.
